Category Archives: Drug Policy

Subscribe to Drug Policy RSS Feed

Veterans’ Affairs Hearing on VA Prescribing Practices

  Around this time last year I wrote an article for Q&B’s Diversity Blog discussing two disturbing trends regarding members of the Armed Forces and specifically veterans.  The increasing suicide rate and abuse of prescription drugs are unfortunate outcomes of the stress that more than 12 years of persistent war has placed on the military.  … Continue Reading

Changes Ahead: New Rules for Painkillers

FDA Announces New Labeling and Postmarket Studies Requirements for Painkillers On September 10, 2013, the FDA announced its plan to issue new regulations for labeling extended-release and long-acting (ER/LA) opioid analgesics intended to treat pain.  According to the FDA, the labeling changes “will include important new language to help health care professionals tailor their prescribing decisions … Continue Reading

Abused Medications Come From Family, Friends

The tragedy and pervasiveness of prescription drug abuse is well-documented.  According to the latest National Survey on Drug Use and Health  released last week, 1.9 million Americans used prescription painkillers for a nonmedical purpose for the first time in 2012.  The tireless efforts of DEA and other law enforcement agencies to address this issue are … Continue Reading

Upcoming DEA Conferences

The DEA has announced an upcoming Manufacturer/Importer/Exporter Conference to be held in June 2013 at the National Harbor, Gaylord National Resort & Convention Center. “The purpose of this conference is to provide a forum to present federal laws and regulations that affect the pharmaceutical and chemical manufacturing, importing, and exporting industry and to discuss practices … Continue Reading

DEA’s Uneasy Relationship with Oxycodone

DEA’s position on oxycodone is clear — more or less. In DEA’s letter to FDA supporting a petition to restrict the approved labeled use of oxycodone to “severe pain,” DEA said that “abuse of prescription opioids have increased markedly over the past decade.”  In the letter DEA also expressed support for the legitimate and beneficial uses of … Continue Reading
LexBlog